- Home
- NX vs TERN Comparison
NX vs TERN Comparison
Compare NX & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NX
- TERN
- Stock Information
- Founded
- NX 1927
- TERN 2017
- Country
- NX United States
- TERN United States
- Employees
- NX N/A
- TERN N/A
- Industry
- NX Metal Fabrications
- TERN Biotechnology: Pharmaceutical Preparations
- Sector
- NX Industrials
- TERN Health Care
- Exchange
- NX Nasdaq
- TERN Nasdaq
- Market Cap
- NX 660.6M
- TERN 710.6M
- IPO Year
- NX N/A
- TERN 2021
- Fundamental
- Price
- NX $14.47
- TERN $7.90
- Analyst Decision
- NX
- TERN Buy
- Analyst Count
- NX 0
- TERN 7
- Target Price
- NX N/A
- TERN $13.99
- AVG Volume (30 Days)
- NX 572.1K
- TERN 1.7M
- Earning Date
- NX 12-11-2025
- TERN 11-12-2025
- Dividend Yield
- NX 2.21%
- TERN N/A
- EPS Growth
- NX N/A
- TERN N/A
- EPS
- NX N/A
- TERN N/A
- Revenue
- NX $1,839,956,000.00
- TERN N/A
- Revenue This Year
- NX $46.73
- TERN N/A
- Revenue Next Year
- NX $0.48
- TERN N/A
- P/E Ratio
- NX N/A
- TERN N/A
- Revenue Growth
- NX 70.18
- TERN N/A
- 52 Week Low
- NX $13.11
- TERN $1.87
- 52 Week High
- NX $32.23
- TERN $9.03
- Technical
- Relative Strength Index (RSI)
- NX 42.67
- TERN 49.14
- Support Level
- NX $13.99
- TERN $7.12
- Resistance Level
- NX $15.83
- TERN $8.87
- Average True Range (ATR)
- NX 0.54
- TERN 0.63
- MACD
- NX 0.15
- TERN -0.08
- Stochastic Oscillator
- NX 50.00
- TERN 44.71
About NX Quanex Building Products Corporation
Quanex Building Products Corp is a manufacturer of components sold to original equipment manufacturers in the building products industry. It manufactures engineered products like window and door components that include flexible insulating glass spacers, extruded vinyl profiles, window and door screens, solar panel sealants and precision-formed metal and wood products among others. Its four operating segments are North American Fenestration being the key revenue driver, European Fenestration, North American Cabinet Components, and Tyman. Geographically, it derives a majority of revenue from the United States.
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.